Radiology in the lead: towards radiological profiling for precision medicine in glioblastoma patients? Editorial comment on Glioblastoma patients with a moderate vascular profile benefit the most from MGMT methylation

Pyrosequencing Analysis of O-6-Methylguanine-DNA Methyltransferase Methylation at Different Cut-Offs of Positivity Associated with Treatment Response and Disease-Specific Survival in Isocitrate Dehydrogenase-Wildtype Grade 4 Glioblastoma

“…This epigenetic silencing of the MGMT gene increases the sensitivity of tumor cells to alkylating chemotherapeutic agents, leading to better treatment responses and potentially prolonged survival [ 18 , 19 ]. The intricate interplay between MGMT methylation status and prognosis underscores the critical role of epigenetics in defining the course of these aggressive CNS tumors, ultimately guiding therapeutic decisions and offering hope to both patients and clinicians [ 3 , 16 , 20 , 21 , 22 , 23 , 24 , 25 ].…”

The prognostic relevance of a gene expression signature in MRI-defined highly vascularized glioblastoma

“…Linking transcriptomic vascular profiles with biomarkers that can be calculated non-invasively and pre-surgically, such as MRI perfusion parameters, could revolutionize the treatment of GB by providing not only the macroscopic information extractable from the MRI itself, but also the molecular biology information of the vascular profile associated with certain values of the MRI parameters. Specifically, establishing an association between the expression of a group of genes and macroscopic vascularity would improve the pre-surgical evaluation of GB patients [ 13 ]. To this end, researchers have investigated the use of differential perfusion parameters, such as relative cerebral blood volume (rCBV), which has been extensively analyzed in the literature as an accurate prognostic marker [ [14] , [15] , [16] ].…”